Table 5

Multivariate models predicting an average allopurinol dose change ≥50 mg/day

Odds Ratio

95% Confidence Interval Lower limit

95% Confidence Interval Upper limit

p-value


Degree of renal impairment

Stage 2 CKD*

0.939

0.729

-1.208

0.623

Stage 3 CKD*

1.218

0.857

-1.732

0.2723

Stage 4 CKD*

2.13

1.38

-3.289

0.0006


Age

0.973

0.962

-0.985

< .0001


Male gender

0.948

0.686

-1.309

0.7455


Geographic region**

West

1.303

0.83

-2.045

0.2507

South

1.314

1.019

-1.693

0.0353

Northeast

1.641

1.141

-2.362

0.0076


Thiazide use during follow-up

1.301

1.035

-1.635

0.0244


Charlson-Deyo Comorbidity Index score

1.164

1.059

-1.279

0.0016


Months of allopurinol use

1.022

1.015

-1.028

< .0001


*The reference group is patients with no CKD.

** The reference group is the Midwest

Fuldeore et al. BMC Nephrology 2011 12:36   doi:10.1186/1471-2369-12-36

Open Data